E F Morand1, M Leech, H Weedon, C Metz, R Bucala, M D Smith. 1. Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Melbourne, South Australia, Australia.
Abstract
OBJECTIVE: Cytokines play an important role in the pathology of rheumatoid arthritis (RA). Macrophage migration inhibitory factor (MIF) is a cytokine with a broad spectrum of actions, including induction of monocyte tumour necrosis factor alpha (TNF-alpha). Evidence of the expression and proinflammatory activity of MIF has recently been demonstrated in RA synovium and in animal models of RA. We wished to assess the relationship between MIF expression in synovium and clinical disease. METHODS: Computer-assisted analysis of the cytokine content of arthroscopically obtained biopsies of RA synovium, using paired samples from eight patients with active and inactive/treated disease, was compared with documented clinical parameters. RESULTS: Synovial MIF immunostaining correlated strongly with disease activity as measured by CRP concentration. Reductions in clinical disease parameters, including CRP, tender and swollen joint counts, were accompanied by significant reductions in synovial MIF. Synovial TNF-alpha, transforming growth factor beta (TGF-beta) and interleukin (IL) 10 also showed a significant reduction in association with reduced disease activity, while IL-1 beta and IL-1 receptor agonist did not. CONCLUSION: The correlation of synovial MIF with disease activity corroborates existing evidence of the role of this cytokine in RA. The demonstration that only MIF and TNF-alpha show significant variation in synovial cytokine content with clinical remission suggests that MIF is an important member of the cytokine hierarchy in RA.
OBJECTIVE: Cytokines play an important role in the pathology of rheumatoid arthritis (RA). Macrophage migration inhibitory factor (MIF) is a cytokine with a broad spectrum of actions, including induction of monocyte tumour necrosis factor alpha (TNF-alpha). Evidence of the expression and proinflammatory activity of MIF has recently been demonstrated in RA synovium and in animal models of RA. We wished to assess the relationship between MIF expression in synovium and clinical disease. METHODS: Computer-assisted analysis of the cytokine content of arthroscopically obtained biopsies of RA synovium, using paired samples from eight patients with active and inactive/treated disease, was compared with documented clinical parameters. RESULTS: Synovial MIF immunostaining correlated strongly with disease activity as measured by CRP concentration. Reductions in clinical disease parameters, including CRP, tender and swollen joint counts, were accompanied by significant reductions in synovial MIF. Synovial TNF-alpha, transforming growth factor beta (TGF-beta) and interleukin (IL) 10 also showed a significant reduction in association with reduced disease activity, while IL-1 beta and IL-1 receptor agonist did not. CONCLUSION: The correlation of synovial MIF with disease activity corroborates existing evidence of the role of this cytokine in RA. The demonstration that only MIF and TNF-alpha show significant variation in synovial cytokine content with clinical remission suggests that MIF is an important member of the cytokine hierarchy in RA.
Authors: Ran Gu; Leilani L Santos; Devi Ngo; HuaPeng Fan; Preetinder P Singh; Gunter Fingerle-Rowson; Richard Bucala; Jiake Xu; Julian M W Quinn; Eric F Morand Journal: Cytokine Date: 2015-01-31 Impact factor: 3.861
Authors: Kristin K Brown; Frances H Blaikie; Robin A J Smith; Joel D A Tyndall; Hongqi Lue; Jürgen Bernhagen; Christine C Winterbourn; Mark B Hampton Journal: J Biol Chem Date: 2009-09-23 Impact factor: 5.157
Authors: Dana W Dunne; Albert Shaw; Linda K Bockenstedt; Heather G Allore; Shu Chen; Stephen E Malawista; Lin Leng; Yuka Mizue; Marta Piecychna; Lin Zhang; Virginia Towle; Richard Bucala; Ruth R Montgomery; Erol Fikrig Journal: PLoS One Date: 2010-06-28 Impact factor: 3.240
Authors: Yvonne C Lee; Lori B Chibnik; Bing Lu; Ajay D Wasan; Robert R Edwards; Anne H Fossel; Simon M Helfgott; Daniel H Solomon; Daniel J Clauw; Elizabeth W Karlson Journal: Arthritis Res Ther Date: 2009-10-29 Impact factor: 5.156
Authors: C A Wijbrandts; S I van Leuven; H D Boom; D M Gerlag; E G S Stroes; J J P Kastelein; P P Tak Journal: Ann Rheum Dis Date: 2008-08-22 Impact factor: 19.103